ibio123
mAbexperimentalCOVID-19
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Sep 29, 2021 (NCT05298813)
Timeline
Indications
Studied for
Mechanism of action
- SARS coronavirusANTAGONIST
SARS coronavirus antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05639166 | Phase 2 | Jan 15, 2023 | Immune Biosolutions Inc |
| NCT05303376 | Phase 1/Phase 2 (Phase 2) | Feb 22, 2022 | Immune Biosolutions Inc |
| NCT05298813 | Phase 1/Phase 2 (Phase 2) | Sep 29, 2021 | Immune Biosolutions Inc |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Immune Biosolutions Inc | For profit | 3 | 3 | 1 | 2021 |
1 organizations
Page 1 / 1